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Ever since the biologic effects of radium were discovered by the radiologist
Becquerel and the dermatologist Besnier in 1901, sources of beta rays (electrons)
have been studied and applied in clinical medicine. Among such sources are
radium, radon, cathode rays, phosphorus 32 and strontium 90.
The introduction of artificially-produced radioactive isotopes made pure beta
emitters readily available for the first time, and it was not long before the biologic
effects of P and later Sr9° on human skin were being studied. Wirth and Raper
(1), Low-Beer (2) (3), and Sinclair and Blondal (4) have performed erythema
studies with 32 and have used this radioisotope in the treatment of selected skin
lesions. Friedell, Thomas and Krohmer (5) (6) and Krohmer (7) have similarly
studied Sr9° in plaque form; their investigations have dealt primarily with the
design and construction of the plaque, its physical measurement, and its appli-
cation in the treatment of eye and a few selected eyelid lesions.
As a result of these earlier studies, we became interested in the dermatologic
applications of Sr90. It appeared that this pure beta emitter with a half-life of
about 22 years had certain practical advantages over 32 which has a half-life
of only 14.3 days. Preliminary to clinical therapeutic applications, however, we
undertook a detailed study of the erythema effect of Sr9° on human skin, since
the previously published articles only briefly commented on the dose of this
beta radiation required to produce an erythematous response. Such a study was
considered important in that the knowledge of the "erythema dose" for a par-
ticular form of radiation often makes for a greater understanding regarding
therapeutic dosage schedules and the sequelae which may result.
THE STRONTIUM 90 APPLICATOR
Source
Sr'° is a fission product, that is, a product of the operation of a nuclear reactor. It is
separated from the other fission products by chemical methods. Sr'° decays with a half-life
of about 22 years, giving off a beta particle of 0.54 Mev energy, and no gamma radiation.
It decays to a radioactive daughter Yttrium 90 (half-life 2.7 days) which gives off one beta
particle of 2.24 Mev energy and no gamma radiation. Thus, a "Sr9° plaque" is actually a
pure beta emitter possessing the half-life of Sr9° and emitting the beta particles of both
Sr9° and y90
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Description
In the search for a Sr9° source of a simpler design than that originally used by Friedell,
et al. (5) (6), and one that would not leak, a plaque was made for us by the Oak Ridge
National Laboratory. Because of the very uneven distribution of the Sr9° in this first plaque,
they designed and constructed another plaque, as follows: A thin ceramic disk about 1 cm
in diameter containing the active Sr9° (approximately 10 millicuries) was placed in a stain-
less steel cup; this was covered by a stainless steel foil 2 mils thick (40 mg/cm2) which was
held in place by a small retaining ring placed around the edge; these parts were soft-soldered
together in order to seal the plaque and to prevent leakage of the radioactive material.
The plaque has an outside diameter of 1.0 cm, an overall thickness of 0.79 cm, and a circular
active area of about 1 cm in diameter. As pictured in Fig. 1 the plaque was mounted inside
of a plastic adaptor of the desired size and fastened to the end of a long metal handle bearing
a shield to protect the hand of the operator.
This plaque has been used for approximately 3 years without any leakage or evidence
of deterioration of the metal parts.
FIG. 1. Sr9° applicator assembly
A—Applicator rod (aluminum)
B—Shield (plastic)
C—Adaptor (plastic) enclosing Sr9° plaque
D—Spacer plate (plastic)
Calibration
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The applicator was calibrated on an ionization chamber designed for the measurement
of beta sources (8). The calibration consists of measuring the ionization per cc of air at the
end of the adaptor as used on the patient. This measurement is then interpreted in terms
of the dose delivered to tissue, in units either of md or rep. The depth dose curves shown
in Fig. 2 were determined by measuring the ionization at the end of the adaptor and by
measuring again with various thicknesses of an appropriate absorber inserted between the
adaptor and the ionization chamber.
a)
0
a)
I
FIG. 2. Relative depth dose curves for Sr9° applicators.
Ordinate: Depth dose in percent of the surface dose.
Abscissa: mm of tissue (phantom assumed to be of unit density (1 mm =
Curve A: Sr° Applicator A—9.5 mm source-skin distance.
Curve B: Sr9° Applicator B—3.2 mm source-skin distance.
Definition of Dose Units
100 mg/cm2)).
One rep is a dose of 93 ergs of absorbed energy per gram of tissue. One mad is a dose of
100 ergs of absorbed energy per gram of tissue. Hence if a tissue receives a dose of X rep,
it receives a dose of 0.93 X rad.
CLINICAL APPLICATION
Patients attending the Skin and Cancer Unit and the Department of Radio-
themapy* of the University Hospital ser.ved as subjects for our study. The antero-
medial aspect of the upper thigh or the lateral aspect of the buttock was the body
surface used in most instances for exposure to the Sr9° applicators. Each subject
received one or more series of tests. A series of tests consisted of 4 to 12 irradiated
sites, each site being about 1.5 cm from the next. To facilitate the spacing, a
* We wish to thank Dr. Milton Friedman for his helpful advice and cooperation. We are
also grateful to his staff for their aid in this study.
Nm. °1 tissue
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plastic plate with holes (Fig. 1D) was used so that the plastic adaptor (Fig. 1C)
holding the Sr9° plaque could be easily and quickly inserted. The spacer plate
was taped to the skin surface of the subject and the Sr9° applicator was inserted
into consecutive openings and kept in place long enough to give the desired dose.
The same Sr9° plaque was employed throughout this study; however, two adap-
tors were used in order to vary the source-skin distance and thereby the intensity
of radiation delivered. These will be referred to as follows:
Applicator A—Sr9° plaque with adaptor A.
Source—skin distance: 9.5 mm
Output: 274 rad/min.*
Aperture, a square, 1 cm on a side.
Applicator B—Sr9° plaque with adaptor B.
Source-skin distance: 3.2 mm
Output: 1030 rad/miri.
Aperture, a circle, 1 cm in diameter.
With Applicator B, the radiation at the skin surface was not uniform and a
definite "hot spot" could be demonstrated by measurement, by autoradiography,
and by clinical biologic response. To overcome this complication, the applicator
was rotated on its central axis through 3600 during the total time of exposure.
A different dosage schedule was employed for each of the applicators. The
following are graphic examples of two exposure series:
Applicator A
Source-skin distance: 9.5 mm
Output: 274 rad/min.
Dose in Rad
Applicator B
Source-skin distance: 3.2 mm
Output: 1030 rad/min.
Dose in Rad
Se
* At the time our study was begun the rep was the accepted unit of tissue dose. In the
present paper, we have converted all values from rep to rad. This accounts for the odd
values noted throughout the text. The rad was adopted as the official unit of tissue dose
at the International Radiological Congress held in Copenhagen during the summer of 1953.
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Nineteen subjects were exposed to the Sr9° applicators. Twenty-three series of
exposures* were made and a total of 195 different sites were irradiated.
Whenever possible the subjects were observed two or three times during the
first week following exposure, twice during the second week, once during the
third week and then once every two weeks up to 100 days. Thereafter the sub-
jects were recalled at longer intervals.
Much difficulty was encountered in reading the erythema and the pigmentation
produced by the radiation. We tried to adhere to the following criteria to desig-
nate our readings:
1+ Very, very slight erythema (and/or pigmentation), no precise border
discernible.
2+ Very slight erythema (and/or pigmentation), with poorly defined borders.
3+ Slight erythema (and/or pigmentation), without sharply defined borders.
4+ Distinct erythema (and/or pigmentation), with sharply defined borders.
In order to standardize the reading of the clinical biologic response, all subjects
were observed with the same lighting. This consisted of a 100 watt incandescent
bulb with a daylight-type blue filter in a portable reflector. In addition, readings
were made under a portable Wood's light. This examination under the Wood's
light was helpful in localizing questionable sites of previous exposure after all
biologic changes visible under the daylight bulb had disappeared.
Due to the many difficulties in interpreting the degree of the reactions, vari-
ation in readings up to one plus undoubtedly occurred. Wherever questionable
reactions such as were recorded at the time of observation, they have been
graphed as 0 reactions; wherever intermediate reactions such as 1 + to 2+,
2+ to 3+ or 3+ to 4+, were recorded at the time of observation, the lowest
value has been graphed. Where a response of increased intensity was noted on
succeeding observations, the most intense reaction was recorded. This will be
the case for Figs. 3, 4, 5, and 6.
In addition to observing erythema and pigmentation, all other skin changes
such as papulation, desquamation and induration were recorded.
RESULTS
The clinical reactions produced by the Sr9° plaque at source-skin distances of
9.5 mm and 3.2 mm were different. The results of our observations are tabulated
in Figs. 3—8.
First Observed Wave of Erythema
Fig. 3 (Applicator A: source-skin distance 9.5 mm; output 274 rad/min.)
This graph shows the results of 89 sites exposed in 9 different series of tests on
6 patients. Fig. 3b shows the breakdown of Fig. 3a giving the various dosages used
and the reactions observed in each of the series.
* Four subjects received two series of exposures.
f Since the majority of our subjects were out-patients, it was not always possible to
make a first reading during the first 48 hours after exposure.
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FIG. 3. First observed wave of erythema.
Record of the most intense erythema produced by Sr9° Applicator A (Sr9° source 9.5 mm
from the surface of the skin; output—274 rad/min.).
Of the 89 sites irradiated with Applicator A, 43 developed some degree of
erythema. No erythema was ever noted at sites receiving 410 rad or less. An
erythematous response was first rioted at 479 rad, and then oniy 3 of the 6 sites
exposed developed at 1+ erythema. In order to produce a 1+ erythema in as
many as 6 out of 8 sites exposed, 547 rad were required.
A progressive increase in intensity of biologic response was noted at sites
receiving from 616 rad, up to and including 821 rad. Erythema was noted at
every skin site receiving 889 rad or more.
The number of cases receiving these higher doses are insufficient to permit
statistical appraisal.
Fig. 4 (Applicator B: source-skin distance 3.2 mm; output 1030 rad/min.).
This graph shows the results of 106 sites exposed in 14 different series of tests
on 13 patients. Fig. 4b shows the breakdown of Fig. 4a giving the various dosages
used and the reactions observed in each of the series. Of the 106 sites irradiated
with Applicator B, 50 developed some degree of erythema* while no erythema
was noted at the remaining 56 sites.
At 684 rad, 7 of the 13 sites exposed gave an erythematous response. In order
* One subject (Case 16) accounts for the positive reactions noted for the two lowest
doses; this extreme sensitivity and degree of response was peculiar iii that there were no
similar reactions among the other 18 subjects tested. Case 23 was also au exception; this
subject was the only one who failed to respond to doses as high as 1200 rad.
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FIG. 4. First observed wave of erythema.
Record of the most intense erythema produced by Sr9° Applicator B (Sr°° source 3.2 mm
from the surface of the skin; output—1030 rad/min.).
to produce a 1+ or greater erythema in as many as 11 out of 14 sites irradiated,
1030 rad were required. It is evident from this graph that as the dose was in-
creased, a larger number of the sites exposed gave erythematous reactions.
The first observed wave of erythema produced by Sr9° beta radiation appeared
within I to 5 days after exposure in almost every instance.
Subsequent Wave of Erythema
In addition to the first observed wave of erythema, a subsequent wave of
erythema, occurring 5 to 10 weeks later, was noted at some of the irradiated sites
in most subjects. Only those subjects who returned for periodic follow-up for
100 or more days following exposure are included in Figs. 5 and 6.
Fig. 5 (Applicator A: source-skin distance 9.5 mm; output 274 rad/min.).
This graph shows the results of 6 exposure series in 4 subjects. Fig. 5b shows
the breakdown of Fig. 5a, giving the various dosages used and the reactions
observed in each of the series. (Cases 5, 8, and 9, as graphed in Fig. 3, did not
a)
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FIG. 5. Subsequent wave of erythema.
Record of the most intense reaction* produced by Sr00 Applicator A (Sr9° source 9.5 mm
from the surface of the skin; output—274 rad/min.).
return for follow-up.) It is evident from the graph that only 4 of the 6 exposure
series developed a subsequent wave of erythema.
Of the 56 sites irradiated with Applicator A which could be followed a sufficient
period of time, 15 developed a subsequent wave of erythema. A minimum Sr9°
dose of 547 rad was required to produce this reaction. While the number of cases
are insufficient statistically, the graph indicates a positive trend to an increasing
number of reactions as the dose increases. There is also a tendency (as observed
in Cases 6 and 7) for more intense reactions at the higher doses.
With Applicator A the subsequent wave of erythema when observed appeared
between 58 and 73 days following irradiation.
Fig. 6 (Applicator B: source-skin distance 3.2 mm; output 1030 rad/min.).
* The word "reaction" as used here and in Fig. 6 means erythema mixed with pigmenta-
tion. When subsequent waves of erythema appeared, they occurred in sites which already
possessed a varying degree of pigmentation. Since it was impossible to evaluate the degree
of erythema alone, while apparing in combination with the pigmentation, the combined
biologic response of erythema with pigmentation was recorded as "reaction".
f This may be explained as follows: Case 1 and 2 represent the same subject given 2
series of tests on the same date. It may be that the subsequent wave of erythema for series
2 occurred during an interval when the subject was not observed.
Case 4 (same subject as Case 3) did not develop a subsequent wave of erythema possibly
because the necessary dose of radiation was not given (cf. with Case 3).
It is particularly interesting that in Case 7 not only was one subsequent wave noted
on the 58th day but another was strongly suspected, starting on the 106th day post-irradia-
tion.
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Fro. 6. Subsequent wave of erythema.
Record of the most intense reaction produced by Sr9° Applicator B (Sr9° source 3.2 mm
from the surface of the skin; output—1030 rad/min.).
This graph shows the results of 9 exposure series in 8 subjects. Fig. 6b shows
the breakdown of Fig. 6a, giving the various dosages used and the reactions
observed in each of the series. (Cases 12, 13, 17, 21, and 23 failed to return for
follow-up.) As the graph indicates, some sites in each of the 9 exposure series
developed a subsequent wave of erythema. Of the 72 sites irradiated with Ap-
plicator B which could be followed a sufficient period of time, 38 developed a sub-
sequent wave of erythema. A minimum Sr9° dose of 342 rad was required to pro-
duce this reaction. At 684 rad, 6 of the 9 exposed sites developed erythema;
at 855 rad, 7 out of 9 sites showed erythema. All of the areas developed erythema
for doses of 1030 md and above. The increased intensity of reaction noted for the
higher doses is apparent.
With Applicator B the subsequent wave of erythema, when observed, was
noted between 32 and 59 days following irradiation. This is earlier than the onset
of the subsequent wave of erythema for Applicator A.
Additional Observations of the Clinical Biologic Reactions
A review of the data obtained during the period of our observations, gives
additional information about the clinical biologic effects produced by Sr9°
Applicators A and B. The observations may be summarized as follows:
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1. Erythema occurred as early as one day following radiation and persisted
as long as 12 days before becoming mixed with pigmentation. The average dura-
tion was 3 to 5 days. There was one exception in which the erythema lasted 30
days (Case 7).
2. This first observed wave of erythema became mixed with pigmentation on
an average between the 4th and 7th days, but as early as the 2nd day for one
subject and the 3rd day for another.
3. The mixed erythema and pigmentation lasted varying periods of time—
from a few days to several weeks. The average was 1 to 2 weeks.
4. The mixed reaction of erythema and pigmentation was followed by pig-
mentation alone. This pigmentation would gradually diminish or again become
mixed with erythema when the subsequent wave of erythema appeared.
5. The subsequent wave of erythema (mixed with pigmentation) lasted vary-
ing periods of time—from 2 to 5 weeks in most instances. In one instance (Case 7)
the erythema lasted 102 days.
The persistence of pigmentation differed from subject to subject, lasting as
long as 504 days in a subject recently re-examined. As a rule, the more intense
the first observed wave of erythema, the greater was the tendency for the ap-
pearance of a subsequent wave of erythema and in turn a more pronounced
residual pigmentation. Where an initial erythema occurred without a subsequent
wave of erythema, the residual pigmentation was persistent but significantly
less in intensity.
Only residual pigmentation has been noted on repeated clinical observations
up to 504 days after exposure. There has been no evidence of atrophy, telan-
giectases or ulceration. Reactions other than erythema and pigmentation were
observed in 11 of the exposure series.* These consisted of papulation, induration,
and desquamation. In all instances these reactions were noted only at 684 rad
or above, more commonly above 760 rad, and usually in conjunction with, or
following, the appearance of the subsequent wave of erythema.
DISCUSSION
It is not the intent nor the scope of this paper to discuss the problems of
defining skin eryihema dose, threshold erythema dose, etc. Because so little was
known about the effects of Sr9° on human skin, we set out to observe and record
the biologic effect of this beta radiation whatever it might be. Therefore, the word
erythema as used in this paper refers to all observed skin reactions ranging from
a very, very slight redness, not at all defined, to a distinct redness with a sharply
defined border.
Many factors make it difficult to arrive at the exact dose of Sr9° beta radiation
required to produce an early erythematous reaction on human skin, or the rela-
tionship of dose to the appearance of the subsequent wave of erythema. Among
these difficulties are 1) the small number of cases irradiated, 2) the inevitable
variations in biologic response of the skin, 3) the lack of more frequent observa-
* Transient reactions may have gone unobserved due to the time intervals between
observations.
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tions of the subjects, 4) the errors of reading erythematous reactions with the
unaided human eye.
Nevertheless it may be concluded that with Applicator A (9.5 mm source-skin
distance), approximately 600 rad produces an erythematous response in 80% of
the subjects tested. This dose is considerably less than the dose of approximately
1000 rad required to produce an erythematous response in 80% of the subjects
tested with Applicator B (3.2 mm source-skin distance).
These figures are in the same general range as those given by Wirth and Raper
(1) for the threshold erythema dose for 32 plaques in contact with the skin and
by Blomfield and Spiers (9) for the erythema dose for radium beta.
Relationship of Source-Skin Distance and Erythematous Response
In order to permit a graphic visualization and statistical analysis of all of the
erythematous reactions caused by the various doses of radiation administered,
our findings were calculated and plotted as mean intensity of reactions.*
I
I
Fro. 7. Mean intensity of reaction of first observed wave of erythema produced by a Sr'°
source.
Curve A: Sr9° Applicator A—9.5 mm source-skin distance.
Curve B: Sr"' Applicator B—3.2 mm source-skin distance.
First Observed Wave of Erythema:
Examination of Fig. 7 shows that the slope of curve A (Applicator A: 9.5 mm
source-skin distance) is steeper than the slope of curve B (Applicator B: 3.2 mm
source-skin distance). This observation indicates that the biologic effect of Sr9°
beta particles is influenced by the source-skin distance. The greater the source-
skin distance, the greater the reaction for any given dose. This difference in
mean intensity of reaction is greater at the higher doses, but tends to disappear
at the smaller doses, since the curves come together as they approach the axis
of abscissae.
* The mean intensity of reaction to a partici.ilar dose equa's the sum of the intensities of
reactions (0, 1+, 2+, 3+, or 4+) divided by the number of sites exposed to that particular
dose.
Dose in Rad
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Subsequent Wave of Erythema:
More than one wave of erythema was noted by Wirth and Raper (1) for P82
and by Friedell et al. (10) for Sr°°. We also observed subsequent waves of ery-
thema at many of the sites irradiated with Sr90. The term subsequent wave (and
not "second wave") has been intentionally chosen as other waves of erythema
may have occurred following the first wave which may have gone unobserved
during the intervals between our examinations.
Fig. 8 shows the subsequent wave of erythema (reaction) (refer to footnote
Fig. 5) plotted in the same manner as shown in Fig. 7 for the first observed wave.
Again it is indicated that the biologic effect of Sr9° beta irradiation (as judged by
the visible reaction produced) is a function of the source-skin distance. Figs. 7
and 8 appear to substantiate one another. The marked steepness of the curves in
Fig. 8 as compared to Fig. 7 may be accounted for by the fact that "reaction"
in Fig. 8 refers to the mixed erythema and pigmentation.
I
Fia. 8. Mean intensity of reaction of subsequent wave of erythema produced by a Sr9°
source.
Curve A: Sr°° Applicator A—9.5 mm source-skin distance.
Curve B: Sr'° Applicator B—3.2 mm source-skin distance.
Relationship of Source-Skin Distance and Time of Onset of Erythematous Response
There was no apparent difference in the time of onset of the first observed wave
of erythema for the Sr9° source at the different distances. However, there was a
difference in the time of onset for the subsequent wave of erythema. It appeared
earlier at the sites irradiated with Applicator B (3.2 mm source-skin distance)
that is, the one with the shorter source-skin distance.
Relationship of Source-Skin Distance, Depth Dose and Biologic Effect
The depth dose curves shown in Fig. 2 demonstrate that the greater the Sr9°
source-skin distance, the greater the depth dose relative to the surface. This sug-
gests that the biologic effect of the Sr9° beta radiations may be a function of
depth dose: the greater the source-skin distance, the greater is the depth dose
1000
Dose in Rad.
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and therefore the greater the biologic effect. For example, Applicator A (9.5 mm
source-skin distance) delivers 50 % of its surface dose at a depth of 0.9 mm in a
tissue equivalent phantom while Applicator B (3.2 mm source-skin distance)
delivers 50% of its surface dose at a depth of 0.7 mm in a tissue equivalent
phantom. Likewise, 25% of the surface dose is delivered at 2.2 mm and 1.7 mm
respectively. It is considered unlikely that the differences in exposure time
(dose-rate) account for the observed differences in reaction.
The "Just Perceptible Eryt hema"—S peculation Concerning its Production
Examination of Fig. 7 indicates that the "just perceptible erythema* appears
at a lower dose for the Sr9° Applicator B (3.2 mm source-skin distance (Curve B))
than for the Sr9° Applicator A (9.5 mm source-skin distance (Curve A)). How-
ever, the uncertainty of the readings at low doses, and the small number of
patients, makes it reasonable that this difference may be due to error and/or
the expected biologic variations in response to radiation (e.g., Case 16, Fig. 4).
It is consistent with the majority of the observations to speculate that a larger
series of observations would show that the two curves cross the axis of abscissae
at approximately the same place. Otherwise stated, it may be speculated that
the "just perceptible erythema" dose may be independent of the differences in
source-skin distance used in this study. Were this the case, it would indicate
that the "just perceptible erythema" is produced by a different mechanism than
the more intense erythematous reactions.
SUMMARY AND CONCLUSIONS
1. The clinical biologic effects produced by strontium 90 beta radiation in 19
subjects are recorded and evaluated.
2. A Sr9° source in the form of a plaque was used with two adaptors designed
to give different source-skin distances. One permitted a source-skin distance of
9.5 mm and the other a source-skin distance of 3.2 mm.
3. Two waves of erythema were observed in most instances following exposure
to the Sr9° source. A first wave appeared in 1 to 5 days. This was followed by a
subsequent wave which appeared earlier for the applicator with the shorter skin
distance, that is, in 32 to 59 days as compared to 58 to 73 days for the applicator
with the longer source-skin distance.
4. In order to produce an erythematous response in 80% of the subjects
tested, approximately 600 rad were required for the Sr9° Applicator A (9.5 mm
source-skin distance); approximately 1000 rad were required for the Sr9° Appli-
cator B (3.2 mm source-skin distance).
5. Our observations indicate that the biologic effects of Sr9° beta radiation, as
judged by the visible reactions produced, is influenced by the source-skin
* The term "just perceptible erythema" is used to designate a degree of erythema which
would be ju.st barely visible to the human eye. It would be expected to appear at some
dose near the point at which the curves for the mean intensity of reaction cross the axis
of the abscissae in Fig. 7.
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distance: the greater the source-skin distance, the greater the reactions for any
given dose.
6. Our observations aiso suggest that the biologic effects of Sr9° beta radiation
may be a function of depth dose: the greater the source-skin distance, the greater
the depth dose and therefore the greater the biologic effects.
7. The "just perceptible erythema" is defined and a speculation concerning its
production is offered.
8. Additional observations of clinical biologic reactions are recorded and
discussed.
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DISCUSSION
DR. JONAS E. SCHREIDER, Walnut Creek, California. I wonder if Dr. Witten
would care to comment on the half value layer of Strontium 90 which I would
assume to be about 1 mm. of tissue as suggested by his lantern slide. I would
like to ask if the clinical applications of a Strontium 90 plaque are equal or
superior to Grenz radiation which can be obtained at higher or lower half value
layers and irradiate larger areas—albeit a different type of radiation.
Du. VIcToR H. Wn'TEN (in closing) Dr. Schreider, in your reference to half
value layer of tissue, I really can't answer you specifically. The paper presents
relative depth dose curves for two Strontium 90 sources as measured in a tissue
equivalent Substance.
In regard to the clinical applications, we didn't intend to discuss that aspect
at all. However, we have treated certain skin lesions with our Strontium 90
plaque. These have been keratoses and superficial basal cell epitheliomas. While
our results have been favorable, we don't think we have treated enough cases nor
followed them long enough to report on them at this time.
The real intent of this paper was to show that there was a subsequent wave
of erythema for Strontium 90 sources, that the time of onset of the subsequent
wave of erythema was influenced by the source-skin distance, that the source-
skin distance altered depth dose and that the depth dose altered the biological
effect; and also to speculate on a mechanism which may be active in the produc-
tion of what we have called the "just perceptible erythema".
